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Abstract
Mutations in LRRK2 play a critical role in both familial and sporadic Parkinson’s disease
(PD). Up to date, the role of LRRK2 in PD onset and progression remains largely unknown.
However, experimental evidence highlights a critical role of LRRK2 in the control of vesicle
trafficking that in turn may regulate different aspects of neuronal physiology. We have ana-
lyzed the role of LRRK2 in regulating dopamine receptor D1 (DRD1) and D2 (DRD2) traffick-
ing. DRD1 and DRD2 are the most abundant dopamine receptors in the brain. They differ in
structural, pharmacological and biochemical properties, as well as in localization and inter-
nalization mechanisms. Our results indicate that disease-associated mutant G2019S
LRRK2 impairs DRD1 internalization, leading to an alteration in signal transduction. More-
over, the mutant forms of LRRK2 affect receptor turnover by decreasing the rate of DRD2
trafficking from the Golgi complex to the cell membrane. Collectively, our findings are con-
sistent with the conclusion that LRRK2 influences the motility of neuronal vesicles and the
neuronal receptor trafficking. These findings have important implications for the complex
role that LRRK2 plays in neuronal physiology and the possible pathological mechanisms
that may lead to neuronal death in PD.
Introduction
Mutations in the leucine-rich repeat kinase 2 gene (LRRK2, PARK8) are the most frequent
genetic causes of Parkinson’s disease, reaching up to 40% in some ethnic groups, Ashkenazi
Jewish and North African Arab Berbers [1]. These mutations cause late-onset, autosomal dom-
inant PD that is clinically and neuropathologically indistinguishable from idiopathic forms [2,
3]. LRRK2 is a member of Roco superfamily proteins, a novel multi-domain family of Ras-like
G-proteins. LRRK2 is composed of different functional and structural domains: armadillo
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repeats (ARM), ankyrin repeats (ANK), leucine-rich repeats (LRR), Ras of complex (Roc), C-
terminal of Roc (COR), kinase and a WD40 domains [4]. Up to date, the PD pathological
mutations have been identified around the central catalytic core of the protein: two mutations
in the Roc domain (N1347H and R1441C/G/H/S), one in the COR domain (Y1699C) and two
in the kinase domain (G2019S and I2020T). In addition, two risk factor mutations for sporadic
PD were identified, respectively in the COR domain (R1628P) and in the WD40 repeats
(G2385R) [4].
Despite the apparent clinical association between LRRK2 mutations and PD, it remains
enigmatic how LRRK2 pathological mutations may contribute to disease onset and progres-
sion. Different experimental results suggest an important role of LRRK2 in the control of vesi-
cle trafficking, and alteration in synaptic vesicle trafficking seems a common theme in PD
pathogenesis [5, 6]. Moreover, many LRRK2 protein interactors belong to protein families
involved in vesicle trafficking regulation inside the cells (among them Rab5 [7], Rab7 [8],
Rab7L [9, 10], Sec16A [11], a subset of Rabs [12], endoA [13]) or in cytoskeleton dynamics
that in turn may modulate vesicle trafficking [14–17].
In neurons, the vesicle trafficking controls fundamental physiological functions such as
neurotransmitter or protein release and uptake, localization of membrane receptors, changes
in plasma membrane composition and, not least, organelle biogenesis. LRRK2 has been impli-
cated in the regulation of receptor trafficking: DRD2 protein level is elevated in LRRK2 over-
expressing mice [18], loss of LRRK2 impairs the activity-dependent targeting of glutamate
receptors into the cell/synapse surface [11], LRRK2 over-expression, mostly the pathological
mutants, alters the level of epidermal growth factor receptor (EGFR) on cell membrane and its
degradation pathway [19].
We have previously shown that the expression of disease-associated LRRK2 mutants lead to
alteration of DRD1 trafficking both in animal and cellular models. In particular, expression of
G2019S LRRK2 determines an increase in DRD1 on the membrane that parallels a decrease in
the vesicle pool [20]. The neurotransmitter receptor level on plasma membrane is determined
by the protein arriving on the cell surface from Golgi/exocytic pathways, the protein leaving
the surface via the endocytic pathway, and eventually the receptor recycling to plasma mem-
brane from the intracellular endosomal pools. Consequently, many different molecular path-
ways could be responsible for the DRD1 trafficking/localization alteration that we observe in
transgenic mice. Based on these considerations, we investigated the molecular mechanism
behind LRRK2 action on DRD1 and extended our analysis to other members of the dopamine
receptor family. DRD1 and DRD2 are the most abundant dopamine receptors in the CNS and
belong to two different receptor classes: D1-class dopamine receptors (D1 and D5) or D2-class
dopamine receptors (D2, D3, and D4) [21, 22]. In addition, alternative splicing of Drd2 gene
generates two major D2 dopamine receptor variants: DRD2S (D2-short) and DRD2L
(D2-long) [23, 24]. Importantly D1- and D2-class dopamine receptors differ in structural,
pharmacological, biochemical properties, as well as in localization and internalization mecha-
nisms [21]. Here we provide evidence that LRRK2 plays an important role in the control of
DRD1 and DRD2 trafficking both in cellular and animal models.
Results
LRRK2 G2019S alters the internalization of dopamine D1 receptor
To investigate the role of LRRK2 in the regulation of dopamine receptor trafficking we gener-
ated and characterized (i) recombinant adenovirus for the expression of different LRRK2 iso-
forms (Fig 1A) and (ii) two different SH-SY5Y stable cell lines expressing either DRD1 or
DRD2L (long isoform) both bearing a C-terminal 3X-FLAG tag (see below).
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Fig 1. Analysis of DRD1 internalization upon dopamine treatment in SH-SY5Y-DRD1 cells untransduced or transduced by WT or different
LRRK2 mutants. (A) Evaluation of LRRK2 expression level upon recombinant adenovirus transduction in SH-SY5Y cells. SH-SY5Y were transduced by
increasing amount recombinant adenoviruses and analysed 48 hours after transduction. Cell lysates were subjected to reducing SDS-PAGE and western
blot. The anti-LRRK2 antibody (MJFF2 c41-2) was used to visualize LRRK2 expression level and β-actin serves as controls for equal loading of samples. (C
and D) DRD1 localization at basal conditions (C) and upon 15 minutes (D) of dopamine treatment of SH-SY5Y-DRD1 cells transduced by the different
recombinant adenovirus for 48h. After agonist treatment the cells were fixed and incubated by the different primary antibodies (anti-FLAG for DRD1 and
anti-LRRK2 (MJFF2) for LRRK2) and with Alexa647-conjugated secondary antibody (red) or Alexa488-conjugated secondary antibody (green) for DRD1 or
LRRK2 respectively. Scale bars = 10μm. (B) Quantification of data obtained in (D) using different LRRK2 mutants upon 15’ of dopamine treatment. The
data represent the mean ± SD. ***p<0,001. One-way ANOVA and Bonferroni post test were used.
https://doi.org/10.1371/journal.pone.0179082.g001
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Using these molecular tools, we analysed the internalization of D1 receptor upon dopamine
treatment in SH-SY5Y-DRD1 cells by confocal microscopy, in the presence or absence of the
different LRRK2 isoforms. LRRK2 expression was obtained by transduction of recombinant
adenovirus for WT or the pathological mutant G2019S LRRK2. As shown in Fig 1C (left
panel), the receptor is mainly localized on the cell membrane in SH-SY5Y-DRD1 at basal con-
ditions, both in the absence or presence of wild type and mutant LRRK2. However, DRD1 is
rapidly internalized upon 5 minutes of dopamine treatment, as shown by the presence of red
dots inside the cells (S1A Fig). On the contrary, the presence of mutant G2019S LRRK2
impairs the receptor internalization. This effect becomes even more evident after 15 minutes
of dopamine treatment (Fig 1D). After 1 hour of dopamine treatment some red dots are still
visible in cells transduced by G2019S LRRK2 (S1B Fig). No significant difference, compared to
WT LRRK2, on D1 internalization was observed in the presence of mutant R1441C or the
dead kinase D1994A LRRK2 (Fig 1B and 1D). Moreover, the DRD1 trafficking alteration due
to G2019S expression seems to be independent of LRRK2 kinase activity since pre-treatment
with a LRRK2 kinase inhibitor (CZC-25146) does not significantly mitigate the G2019S
LRRK2 effect (S2A and S2B Fig)
The reduced internalization of DRD1 observed in the presence of G2019S LRRK2 even at
early time points of dopamine treatment indicates an alteration of endocytosis rather than an
increase in recycling/exocytosis pathway. To get a quantitative evaluation on the alteration of
DRD1 trafficking in the presence of G2019S LRRK2 we performed a biotin degradation pro-
tection assay (BPA) [25]. As illustrated in Fig 2A and 2B the level of DRD1 internalized upon
15 minutes of dopamine treatment is strongly reduced in G2019S LRRK2 transduced cells
compared to untransduced cells. It is interesting to note the slight but significant shift in
DRD1 molecular weight upon agonist treatment. In fact, in absence of any phospho-specific
antibody for DRD1, the DRD1 shift has been largely used to measure the receptor phosphory-
lation/activation state [26].
Since different experimental evidence [27] suggests a potential role of synuclein in the con-
trol of vesicle trafficking, we have analyzed the possible effect of synuclein expression on
DRD1 trafficking upon dopamine treatment in the same experimental conditions. As shown
in Fig 2C and 2D no significant effect is detectable in the presence of either WT or pathological
mutant A53T synuclein transduced by recombinant adenovirus.
LRRK2 alters the dopamine D2 receptor trafficking
While, as expected, DRD1 is largely localized on the cell membrane, instead DRD2L is partially
present inside SH-SY5Y cells, likely in vesicle structures and in the Golgi apparatus (see
below). This is consistent with reports from other groups using similar DRD2L stable clones
[28, 29]. Moreover, in SH-SY5Y cells, the dopamine receptor trafficking differs between the
different subtypes. DRD1 is recycled back to the plasma membrane while DRD2 is mainly
degraded after receptor internalization upon agonist treatment [25].
First of all, we have evaluated possible alteration in DRD2 localization in the presence of
LRRK2 over-expression. Stable SH-SY5Y-DRD2 cells were transduced by the different LRRK2
isoforms and DRD2 cellular distribution was analyzed 48 hours after transduction. As shown
in Fig 3A and 3B, the over-expression of LRRK2 pathological mutants determines a significant
accumulation of DRD2 into the cells compared to LRRK2 WT or dead kinase and even more
compared to untransduced cells. Co-staining with a trans Golgi specific marker (TGN46)
reveals that intracellular DRD2 is mainly localized into the Golgi apparatus (3A-B). No signifi-
cant differences in DRD2 membrane level were observed in the different experimental condi-
tions by confocal analysis (Fig 3A) or by BPA labelling (Fig 3C).
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Fig 2. Evaluation of DRD1 intracellular and extracellular level by BPA upon dopamine treatment in SH-SY5Y-DRD1 cells untransduced or
transduced by WT or G2019S LRRK2. (A) Cells stably expressing FLAG-tagged DRD1 were transduced by the different LRRK2 isoforms. 48h after
transduction the cell membrane protein were labeled by biotin. After 15 minutes of dopamine treatment the cell surface-biotinylated receptors were
stripped and the cell lysates subjected to purification by streptavidin-agarose. Total and immunoprecipitated (beads) proteins were visualized by
western blot using specific antibody for the indicated proteins. β-actin serves as controls for equal loading of samples. (B) Densitometric analysis of
data obtained in (A) nomalized by the untransduced cells. The data represent the mean ± SD. ***p<0,001. One-way ANOVA and Bonferroni post test
were used. (C and D) DRD1 localization at basal conditions (C) and upon 15 minutes (D) of dopamine treatment of SH-SY5Y-DRD1 cells transduced
or not by alpha-synuclein WT or A53T. After agonist treatment the cells were fixed and incubated with the different primary antibodies (anti-FLAG for
DRD1 and anti-synuclein (Millipore) for alpha-synuclein) and with Alexa647-conjugated secondary antibody (red) or Alexa488-conjugated secondary
antibody (green) for DRD1 or synuclein respectively. Scale bars = 10μm.
https://doi.org/10.1371/journal.pone.0179082.g002
Role of LRRK2 in the regulation of dopamine receptor trafficking
PLOS ONE | https://doi.org/10.1371/journal.pone.0179082 June 5, 2017 5 / 22
We reasoned that a change in DRD2 localization may result in alteration in DRD2 total
protein level in the presence of LRRK2 over-expression. Stable SH-SY5Y-DRD2 cells were
transduced by the different LRRK2 isoforms and the total DRD2 protein level was analyzed 48
hours after transduction. As shown in Fig 4A and 4B, the over-expression of LRRK2 mutants
determines a slight but significant increase in DRD2 total protein level compared to LRRK2
WT and an important increase compared to untransduced cells. In the same experimental
conditions, no significant difference in DRD1 total levels was detectable in the presence of any
LRRK2 transgenes as shown in Fig 2A. We deeply analysed whether the DRD2 increased pro-
tein level may be due to a higher transcription rate or an increase in protein synthesis. There-
fore, we have analyzed the DRD2 mRNA level by real-time PCR in the presence or absence of
G2019S LRRK2. No difference in DRD2 mRNA level was detected 48 hours after adenoviral
Fig 3. Analysis of LRRK2 effect on DRD2 cell localization. (A) SH-SY5Y cells stably expressing FLAG-tagged DRD2 were transduced by WT or
different LRRK2 mutants. 48h after transduction, the cells were fixed and incubated with the different primary antibodies (anti-FLAG for DRD2 and anti-
LRRK2 antibody (MJFF2 c41-2) for LRRK2 and anti-TGN46 for trans-Golgi staining). Scale bars = 10μm. (B) Quantification of data obtained in (A) and
using different LRRK2 mutants. The data represent the mean ± SD. *p<0,05; **p<0,01; ***p<0,001. One-way ANOVA and Bonferroni post test were
used. (C) Cells stably expressing FLAG-tagged DRD2 were transduced by the different LRRK2 isoforms. 48h after transduction the cell membrane
protein were labeled by biotin. After 15 minutes of dopamine treatment the cell surface-biotinylated receptors were stripped and the cell lysates
subjected to purification by streptavidin-agarose. Total and immunoprecipitated (beads) proteins were visualized by western blot using specific antibody
for the indicated proteins. β-actin serves as controls for equal loading of samples.
https://doi.org/10.1371/journal.pone.0179082.g003
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transduction compared to untransduced cells (S3C Fig). We then compared de novo protein
synthesis after short (two hours) protein translation block by puromycin. As shown in Fig 4C
and 4D, the level of DRD2 protein synthesis was comparable between the different experimen-
tal samples at early time points (1 or 2 hours), strongly indicating that LRRK2 expression does
not alter DRD2 protein translation rate. However, at 3 hours we can detect significant differ-
ences in DRD2 level in the presence of G2019S LRRK2 that likely reflects an alteration in local-
ization and/or degradative pathways. No differences in beta-actin protein levels were detected
Fig 4. Analysis of LRRK2 effect on DRD2 total protein level. (A) SH-SY5Y cells stably expressing FLAG-tagged DRD2 were transduced by the
different LRRK2 isoforms. 48h after transduction, protein extracts were prepared and subjected to SDS-PAGE and western blot. The indicated proteins
were visualized by western blot using specific antibody. β-actin serves as controls for equal loading of samples. (B) Quantification of data obtained in (A).
The data represent the mean ± SD. *p<0,05; **p<0,01; ***p<0,001. One-way ANOVA and Bonferroni post test were used. (C) SH-SY5Y-DRD2
transduced as in (A) were treated for 2 hours by puromycin (+), then the compound was removed and the new DRD2 protein synthesis was analyzed at
1h, 2h and 3h. Cell lysates were prepared and analysed by western blot. (D) Relative band densitometry of data obtained in (C) normalized by the
untransduced cells. The data represent the mean ± SD. ***p<0,001 Two-way ANOVA and Bonferroni post test were used. (E) SH-SY5Y-DRD2
transduced as in (A) were treated for different time points (15’, 30’, 45’, 60’) by puromycin, then cell lysates were prepared and analyzed by western blot.
DRD2 decrease was visualized by specific anti-FLAG antibody. (F) Relative band densitometry of data obtained in (D) normalized by the untransduced
cells. The data represent the mean ± SD.
https://doi.org/10.1371/journal.pone.0179082.g004
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by this short puromycin treatment. Then, we have evaluated the DRD2 turnover by blocking
protein synthesis, by puromycin treatment, 48 hours after transduction of SHSY5Y-DRD2
cells by WT or G2019S LRRK2 recombinant adenovirus. As shown in Fig 4E and 4F, the deg-
radation rate slower in G2019S LRRK2 cells than in untransduced cells. Roughly 50% of
DRD2 is degraded in untransduced cells after 15 minutes of puromycin treatment compared
to the roughly 20% decrease in cells transduced by G2019S LRRK2. Cells transduced by
LRRK2 WT show an intermediate phenotype.
Taken together, these data indicate that LRRK2 pathological mutants may slow down the
DRD2 trafficking between the Golgi and the plasma membrane and likely its half-life, since
the fraction of DRD2 reaching the cell membrane is degraded upon internalization. Our
results do not exclude a direct involvement of LRRK2 in the autophagic-lysosomal pathways
that in turn may affect the Golgi physiological function.
LRRK2 expression alters both DRD1 and DRD2 signalling
To follow the DR activation pathways we assayed the phosphorylation of Extracellular signal
Regulated Kinases 1 and 2 (ERK1 and ERK2). In fact, results obtained from different cell cul-
ture systems suggest that both D1- and D2-class dopamine receptors can regulate ERK phos-
phorylation/activation [30–33].
SH-SY5Y-DRD1- or -DRD2 cells were transduced by recombinant adenovirus expressing
WT or G2019S LRRK2. Fourty-eight hours after transduction, cells were kept for 1 hour with-
out serum and dopamine was added at different times (15, 30 or 60 minutes). Protein extracts
were then analyzed by western blot using a specific antibody against phospho-ERK. As shown
in Fig 5A and 5B, the presence of G2019S LRRK2 determines a strong ERK activation upon
DA treatment in the SH-SY5Y-DRD1 cells and this activation is more persistent than in con-
trol untransduced cells, with the cells transduced by WT LRRK2 showing an intermediate phe-
notype. Comparable effect on ERK phosphorylation was observed in SH-SY5Y cells expressing
DRD2 and transduced by the different LRRK2 isoforms upon dopamine stimulation (Fig 5C
and 5D). These results suggest that the over-expression of WT and G2019S LRRK2 modifies
the DRD1 and DRD2 signalling, most probably through an alteration of receptor trafficking.
To further analyze the DRD1 signalling in the presence of LRRK2, we measured cAMP genera-
tion upon dopamine treatment in SH-SY5Y-DRD1. As shown in Fig 5E, DA exposure of
SH-SY5Y-DRD1 transduced by G2019S LRRK2 determines a stronger and significant decrease
of ATP level (that indicates an increase in cAMP generation).
Analysis of DRD1 trafficking in LRRK2 animal models
We first tested the most suitable commercial anti-DRD1 or anti-DRD2 antibodies to detect
endogenous proteins in mouse brain and primary neurons. The commercial anti-DRD1 anti-
body (Sigma D2944) is able to detect the DRD1 protein either by western blot (without boiling
the protein samples) or by immunofluorescence. Unfortunately, under our experimental con-
ditions, no commercial anti-DRD2 antibodies were able to detect the receptor either by west-
ern blot or immunofluorescence. As a consequence we have analyzed the tissues and primary
neurons only for DRD1 expression.
We extended our study on DRD1 trafficking to the striatum of 4-month old male mice
knock-in for G2019S LRRK2 compared to age-matched WT LRRK2 mice. Western blot analy-
sis showed no difference in DRD1 level in total, membrane or vesicle fractions between WT or
G2019S LRRK2 knock-in mice, either in basal conditions or upon treatment with apomor-
phine (3 mg/Kg) for 25 minutes to stimulate DR trafficking (S3A and S3B Fig). However,
immunofluorescence analysis on striatal sections highlighted significant differences between
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the two genotypes. In particular, 25 minutes of apomorphine treatment resulted in a pro-
nounced dotted DRD1 staining (likely representing vesicle structures) in WT compared to
G2019S knock-in mice (Fig 6B and 6C). No significant differences were visible in saline treated
animals between the two different genotypes.
Fig 5. Analysis of DRD1 and DRD2 signalling upon dopamine treatment in SH-SY5Y-DRD1 or -DRD2 stable lines untransduced
or transduced by WT or G2019S LRRK2. (A) Cells stably expressing FLAG-tagged DRD1 were transduced by the different LRRK2
isoforms. 48h after transduction the cell were treated for different time points (15’, 30’, 60’) by dopamine. Cell lysates subjected to
western blot using specific antibody for the indicated proteins. β-actin serves as controls for equal loading of samples. (B) Relative band
densitometry for pERK of data obtained in (A) normalized by untransduced and untreated cells. The data represent the mean ± SD.
**p<0,01; ***p<0,001. Two-way ANOVA and Bonferroni post test were used. (C) Cells stably expressing FLAG-tagged DRD2 were
treated as before and analyzed by western blot. (D) Relative band densitometry for pERK of data obtained in (C) normalized by
untransduced and untreated cells. The data represent the mean ± SD. **p<0,01. Two-way ANOVA and Bonferroni post test were used.
(E) The SH-SY5Y-DRD1 were treated as before and analyzed for cAMP level at basal level (-DA) or upon 15 minutes of dopamine
treatment (+DA). The assay is measuring the ATP decrease due cAMP generation. ***p<0,001. One-way ANOVA and Bonferroni post
test were used.
https://doi.org/10.1371/journal.pone.0179082.g005
Role of LRRK2 in the regulation of dopamine receptor trafficking
PLOS ONE | https://doi.org/10.1371/journal.pone.0179082 June 5, 2017 9 / 22
Fig 6. Analysis of DRD1 internalization in G2019S LRRK2 knock-in mice. (A and B) DRD1 localization/
internalization at low (A) and high magnification (B) upon 25 minutes of saline (saline) or apomorphine treatment
(apomorphine) of G2019S LRRK2 knock-in mice or WT. After agonist treatment the mouse brain were quickly
dissected and frozen in embedding medium. Cryostat sections were incubated with the different primary antibodies
(anti-DRD1 or histone H4) and with Alexa488-conjugated secondary antibody (green) or Alexa647-conjugated
secondary antibody (red) for DRD1 or H4 respectively. Scale bars = 250 μm and 25μm for A and B respectively. (C)
Quantification of data obtained in (B) indicating the percentage of dotted nuclei obtained by the analysis of at least
twenty high magnification confocal pictures for each animal. The data represent the mean ± SD. **p<0,01. Two-
way ANOVA and Bonferroni post test were used.
https://doi.org/10.1371/journal.pone.0179082.g006
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To further support these results we analysed the DRD1 trafficking in primary striatal neu-
rons isolated from the same WT or G2019S LRRK2 knock-in mice. In primary neurons DRD1
is mainly detected as small fluorescent puncta along the membrane surface of neurites (Fig
7A) and [34]; upon agonist treatment, the labelling extends to the soma and the neurite puncta
appear larger and brighter (Fig 7C and 7E) and [34]. The presence of G2019S LRRK2 deter-
mines, at basal level, a significant decrease in fluorescent puncta size (Fig 7A and S2C Fig) in
neurites compared to WT primary striatal neurons. Moreover, upon agonist treatment, DRD1
localization/trafficking is significantly altered in the presence of G2019S LRRK2. In particular,
at 15 minutes of dopamine treatment, in WT primary neurons a significant soma staining is
visible compared to G2019S neurons (roughly 44% in WT vs 10% in G2019S) (Fig 7C and 7G);
at 60 minutes, the DRD1 staining is largely diffused in knock-in compared to the brighter
DRD1 staining of neurites and soma in WT primary neurons (Fig 7E and 7G).
Discussion
The catecholaminergic neurotransmitter dopamine acts by binding five specific G protein-
coupled dopamine receptors (D1, D2, D3, D4, and D5) and controls fundamental physiologi-
cal functions ranging from the control of voluntary movement, reward pathways, hormonal
regulation and, not least, hypertension. Among them, DRD1 and DRD2 are the most abun-
dant. Both D1 and D2 receptors are highly expressed along the nigrostriatal, mesolimbic, and
mesocortical pathways. Transcripts from the Drd2 gene lead to the generation by alternative
splicing of two major D2 dopamine receptor variants that have been termed DRD2S
(D2-short) and DRD2L (D2-long) [23, 24]. The DRD2 alternative splicing between introns 4
and 5 determines the presence of 29 amino acids in the third intracellular loop that are lacking
in the short isoform. DRD2L and DRD2S have distinct anatomical, physiological, signalling
and pharmacological properties. D2S has been shown to be expressed at higher level pre-syn-
aptically and to be mostly involved in autoreceptor functions, whereas D2L is predominantly a
postsynaptic isoform [22]. Interestingly, DRD2L and DRD2S also show a different cellular dis-
tribution in neuroblastoma NG108-15 cells, with DRD2S mainly localized into cell membrane
and DRD2L distributed between the Golgi apparatus and the plasma membrane [29]. The
dopamine receptor trafficking may have a prominent role in the regulation of dopaminergic
neuron physiology and, in fact, many studies show both in animal models of Parkinson’s dis-
ease, as well as in patients, that the density of D1 and D2 receptors changes although this alter-
ation could be merely in association with the developing supersensitivity due to DA
denervation. Interestingly, recently it has been shown an important role of dopamine D1
receptor in the control of the immune systems by negatively regulating the inflammasome
[35]. Extensive experimental evidence indicates that inflammatory processes are instrumental
in neuronal cell death in PD and LRRK2 seems to have a prominent role in inflammatory cells.
DRD1 rapidly internalizes in response to dopamine and recycles in vivo [36, 37], in con-
trast, DRD2 is significantly down regulated in vivo after prolonged drug abuse [38], in animals
with increased dopamine tone due to deletion of the dopamine transporter [39], or after
chronic low doses of D2R agonists [40]. These data parallel those obtained in the majority of
experiments using cultured cells stably expressing DRD1 or DRD2 [25], although with some
discrepancies for DRD2 [28]. Our SH-SY5Y cell lines largely recapitulate the dopamine recep-
tor trafficking observed in vivo and in vitro in most of experimental models. In these cells,
LRRK2 plays an important role in the control of DR trafficking likely by a modulation of vesi-
cle trafficking. In SH-SY5Y cells stably expressing the DRD1, expression of G2019S LRRK2
determines a strong impairment in DRD1 internalization upon dopamine treatment. This
effect is not visible in the presence of either WT or A53T synuclein, excluding any possible
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Fig 7. Analysis of DRD1 localization/trafficking in striatal primary neurons from WT and G2019S LRRK2 knock-in. (A, C and E) DRD1
trafficking at basal conditions (A) or upon 15 (C) or 60 minutes (E) of dopamine treatment on DIV7 striatal primary neurons isolated from G2019S
LRRK2 knock-in mice or WT. After agonist treatment, the cells were fixed and incubated with the different primary antibodies (anti-DRD1 or beta III
tubulin) and with Alexa488-conjugated secondary antibody (green) or Alexa647-conjugated secondary antibody (red) for DRD1 or beta tubulin
respectively. Scale bars = 20μm (B, D and F) High magnification of DRD1 neurite labelling at basal conditions (B) or upon 15 (D) or 60 minutes (F) of
dopamine treatment. Scale bars = 10μm. (G) Quantification of data obtained in (7A, 7B, 7C, 7D, 7E and 7F). The data represent the percentages of
diffuse, somato-neuritic and neuritic D1 puncta distribution in D1 positive neurons from two independent replicates and are represented as
mean ± SEM. *p<0,05; ***p<0,001. Two-way ANOVA and Bonferroni post test were used.
https://doi.org/10.1371/journal.pone.0179082.g007
Role of LRRK2 in the regulation of dopamine receptor trafficking
PLOS ONE | https://doi.org/10.1371/journal.pone.0179082 June 5, 2017 12 / 22
artefact in our assay due to recombinant protein expression or to adenovirus transduction.
The reduced internalization of DRD1 in the presence of G2019S LRRK2, even at short time
treatment (5 minutes), strongly suggests an alteration in endocytosis more than an increase in
recycling/exocytosis pathway. Importantly, these results extensively mirror the alteration in
DRD1 trafficking observed in primary knock-in neurons expressing the G2019S LRRK2 at
endogenous level. In particular, wild type primary neurons exhibit extensive DRD1 positive
clusters of neuronal soma upon dopamine treatment that is significantly reduced in knock-in
neurons. Moreover, the G2019S expression per se determines a significant alteration in the size
of DRD1 puncta staining in neurites, strongly suggesting an important effect of G2019S patho-
logical mutant on DRD1 localization/clustering.
A DRD1 clustering/internalization impairment, upon apomorphine treatment, is detected
also on brain sections, by immunofluorescence analysis, in G2019S LRRK2 knock-in mice
compared to WT mice. Unfortunately, we were not able to confirm these data by DRD1 west-
ern blot analysis on striatal protein extracts of these animals, but this discrepancy could be
explained by the complexity of the striatal tissue; for instance, striatal neurons differ in terms
of firing rate and timing in response to agonist stimulation.
The internalization impairment is likely independent from DRD1 phosphorylation, since
the receptor band undergoes a similar molecular weight shift when analysed by SDS-PAGE in
the absence or presence of WT or G2029S LRRK2. The DRD1 trafficking alteration in the pres-
ence of G2019S LRRK2 parallels a change in its signalling, with a higher cAMP generation and
ERK phosphorylation, strongly suggesting that the impairment in receptor internalization
may alter signalling transduction shutdown. Taken together, our results indicate that G2019S
LRRK2 is altering some molecular mechanism that mediates the internalization of DRD1 fol-
lowing the receptor phosphorylation due to agonist treatment but also the basal distribution of
the receptor in unstimulated conditions.
An alteration in receptor trafficking is detectable also in our SH-SY5Y-DRD2 stable line.
All LRRK2 pathological mutants lead to a significant accumulation of DRD2 into the Golgi
apparatus compared to WT LRRK2 or untransduced cells. These results are of particular inter-
est since all LRRK2 pathological mutants show a similar phenotype suggesting the possibility
of a common or converging pathological mechanism. The DRD2 accumulation into the Golgi
correlates with a significant increase of DRD2 total protein levels. The presence of any LRRK2
variant does not significantly alter the DRD2 transcriptional or translational rate. Conversely,
expression of mutant LRRK2s determines a slight but significant decrease in DRD2 degrada-
tion (compared to untransduced or WT LRRK2) likely due to the DRD2 accumulation into
the Golgi. Interestingly, the membrane level of DRD2 in the presence of WT or G2019S
LRRK2 are quite similar despite significant differences in total protein level, suggesting that
either a small amount of DRD2 is slowly accumulating into the Golgi or that other compensa-
tory mechanisms take place on the cell membrane. A possible explanation might be that physi-
ologically a certain amount of DRD2 is kept into the Golgi apparatus (and maybe also in the
outpost Golgi in neurons) and that mutant LRRK2s affect its vesicle-mediated transport to the
cell membrane. We can speculate that LRRK2 is part of a protein complex that negatively regu-
lates the Golgi-membrane trafficking. Over-expression of WT LRRK2 and even more the path-
ological mutant is likely increasing the formation/activity of this complex, that may partially
lock the DRD2 into the Golgi apparatus. A different hypothesis could be a more general alter-
ation in Golgi apparatus, for instance LRRK2 seems to affect Golgi clearance by autophagy
[10]. As previously mentioned, different LRRK2 interactors belong to protein families involved
in the regulation of vesicle trafficking [7, 9–13] or involved in the regulation of the cytoskele-
ton dynamics that in turn may modulate vesicle trafficking [14–17]. Any of these LRRK2 inter-
actions may be responsible for DRD1 or DRD2 trafficking modulation that we observe in the
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presence of LRRK2. Our data correlate, to a different extent, to the alteration of DR level or sig-
nalling observed in LRRK2 mouse models. In particular, the PKA-dependent phosphorylation
of GluR1 is aberrantly enhanced in the striatum of young and aged LRRK2-null mice after
treatment with a DRD1 agonist [14] and the total DRD2 protein level is higher in mice over-
expressing WT LRRK2 [18]. Moreover, our results correlate with accumulating evidences that
demonstrate a critical role of LRRK2 in the vesicle trafficking machinery that transports pro-
teins from dendritic ER exit sites to Golgi outpost and to dendritic surface [11]. In particular,
it has been reported that either LRRK2 loss or R1441C missense mutation impair the activity-
dependent trafficking of NMDRs in neurons [11].
Fig 8 summarizes a general view that arises from our and other published results on the
involvement of LRRK2 in the regulation of dopamine receptor trafficking. Mutant LRRK2s
modulate the DRD2 protein level likely affecting the trafficking from Golgi to cell membrane.
The intacellular DRD2 is locked into the trans Golgi as indicated by the significant overlap
with the TGN46 marker. Interestingly, this effect is common to all LRRK2 pathological
mutants. More complex is the involvement of LRRK2 in the control of DRD1 trafficking. Only
G2019S LRRK2 impairs DRD1 internalization upon dopamine treatment. We can speculate
about some specific pathways altered by G2019S LRRK2 mutant likely related to its hyperac-
tive kinase function compared to other LRRK2 pathological mutants, although this view is
slight challenged by the recent discovery that the majority of LRRK2 mutations in the cellular
context, but not in vitro, exhibit increased phosphorylation of its possible substrates [12].
Further experiments are required to better understand the molecular mechanisms of
LRRK2 regulation of dopamine receptor trafficking and to determine whether this effect is




Male homozygous LRRK2 G2019S KI mice backcrossed on a C57Bl/6J background were raised
at the University of Ferrara [41, 42]. Male non-transgenic wild-type (WT) mice were litter-
mates obtained from the respective heterozygous breeding. Mice employed in the study were
kept under regular lighting conditions (12 h light/dark cycle) and given food and water ad libi-
tum. Experimental procedures involving the use of animals were approved by the Italian Min-
istry of Health (license 318/2013-B). Mice were killed by rapid cervical dislocation, adequate
measures were taken to minimize animal pain and discomfort.
Reagents and solutions
Tween1 20 (Polyethylene glycol sorbitan monolaurate), protease inhibitor cocktail, Dopamine
hydrochloride, IGEPAL1 CA-630 (Octylphenoxy poly(ethyleneoxy)ethanol), L-Glutathione
reduced, Streptavidin−Agarose from Streptomyces avidinii, Collagen type IV, IBMX (3-Isobu-
tyl-1-methylxanthine), Ro 20–1724 (4-(3-Butoxy-4-methoxybenzyl)imidazolidin-2-one), R-
(−)-Apomorphine hydrochloride hemihydrate were obtained from Sigma-Aldrich (Milano,
Italy). EZ-Link™ Sulfo-NHS-Biotin was from Thermo Scientific. LRRK2 inhibitors: CZC-
25146 and HG10-102-01 from Calbiochem. The phosphate-buffered saline (PBS) solution was
made using NaCl (137 mM), KCl (2.7 mM), Na2HPO4 (8.1 mM), KH2PO4 (1.47 mM) from
Sigma and then adjusted to pH 7.4. Dulbecco’s modified Eagle’s medium (DMEM)–F12, Fetal
Bovine Serum (FBS), Streptomycin/Penicillin, Geneticin-G418 were purchased from Life
Technologies.
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Plasmid constructions
cDNA corresponding to human LRRK2 (accession no. NM_198578) was RT—PCR amplified
from human lymphoblast mRNA and cloned as previously described in [43]. PacI recognition
site on LRRK2 cDNA was mutagenized by site-directed mutagenesis (forward TTGAGAAAT
TAATCAAACAGTGTTTG, reverse CAAACACTGTTTGATTAATTTCTCAA) without changing
the amino acidic sequence. pShuttle2-LRRK2 (WT or R1441C or D1994A or G2019S) were
obtained by digestions of cDNAs corresponding to human LRRK2 without PacI restriction
site with NotI and XbaI and subcloned in DraI/XbaI cloning sites in pShuttle2 vector (Clon-
tech). Expression cassettes containing LRRK2 cDNAs were excised from pShuttle2 and sub-
cloned into pAdeno-X vector according to Adenoviral-X Expression System 1 (Clontech).
Plasmids to generate DRD1 or DRD2 stable cell lines were obtained as previously described in
[20].
Fig 8. Model for mutant LRRK2 action in the alteration of dopamine receptor trafficking. The LRRK2 pathological mutant
G2019S and R1441C alter the DRD2 protein localization likely affecting the DRD2 trafficking form the Golgi to cell membrane.
Moreover the mutant G2019S is negatively regulating the DRD1 internalization upon dopamine stimulation. For both dopamine
receptors expression of the mutant LRRK2 alter signalling pathways upon dopamine stimulation.
https://doi.org/10.1371/journal.pone.0179082.g008
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Adenoviral delivery
Adenoviral particles were produced and titrated using the Adenoviral-X Expression System 1
(Clontech) according to manufacturer’s instruction. Cells were transduced by adenoviral parti-
cles (10–30 pfu/cell) in DMEM-F12 and incubated at 37˚C for 1 h. The transduced cells (usu-
ally more than 90% expressing LRRK2) were analyzed 48h transduction.
Cell lines and SH-SY5Y stable clones
Human neuroblastoma SH-SY5Y cells (ATCC number CRL-2266) were grown in DMEM–
F12, 10% Fetal Bovine Serum (FBS) at 37˚C. The plasmid pcDNA3.1 containing cDNAs cod-
ing for DRD1-Flag or DRD2-Flag were transfected using Lipofectamine1 LTX Reagent (Life
Technologies) according to the manufacturer’s protocol. The different SH-SY5Y clones were
maintained under selection by 400 μg/mL of G418. Individual clones were picked after 14 days
of selection, moved in a 96 well plate, and maintained under selective medium until confluence
growth. Different individual clones were analyzed for DRD1 or DRD2 expression by western
blot and immunofluorescence.
Biotin protection/degradation assay (BPA)
1x106 SH-SY5Y-DRD1 or SH-SY5Y-DRD2 cells were grown in a collagen type IV (Sigma-
Aldrich) coated 6-well plates. After 24 hours, cells were transduced by recombinant adenovirus
and 48 later subjected to the biotin protection assay protocol as described in [25]. Briefly, cells
were treated with 0.3 mg/ml Sulfo-NHS-SS-Biotin for 30 min at 4˚C. Cells were then washed
in PBS 1X 1 mM MgCl2, 0.1 mM CaCl2, pH 8.2 and placed in DMEM–F12 pre-warmed
medium for 15 min before treatment with 10μM Dopamine hydrochloride (or no treatment).
After ligand treatment, plates were washed in PBS 1X containing 1 mM MgCl2, 0.1 mM CaCl2,
pH 8.2, and remaining cell surface-biotinylated receptors were stripped in 75 mM NaCl, 1 mM
MgCl2, 0.1 mM CaCl2, 50 mM reduced glutathione (GSH), 80 mM NaOH, 10% FBS pH 8.6 at
4˚C for 30 min. Cells were then washed in PBS 1X containing 1 mM MgCl2, 0.1 mM CaCl2,
pH 8.2 and lysed by 150 mM NaCl, 1% NP40, 20mM Tris-HCl pH 7.5, protease inhibitor cock-
tail. Cellular debris were removed by centrifugation at 13,000xg. Cleared lysates were precipi-
tated by Streptavidin-Agarose beads overnight at 4˚C. Beads were washed 4 times with 20
mM, 150 mM NaCl, 1% IGEPAL, 20mM Tris-HCl pH 7.5. Samples were then resolved by
SDS-PAGE.
Subcellular fractionation of cells or mouse tissues
Tissues from 4 months old LRRK2WT or LRRK2G2019S KI male mice were quickly dissected
and frozen. Subcellular fractionation was conducted as described in (40). Briefly, striatum
were homogenized in ice-cold homogenization-buffer (320 mM sucrose, 4 mM HEPES, pH
7.4, protease inhibitor cocktail (Sigma)). The homogenates were centrifuged at 1000xg for 10
min to produce the pellet containing nuclei and large debris fraction (P1). The supernatant
(S1) was further fractionated into pellet (P2 containing the membrane fraction) and superna-
tant (S2) by centrifugation at 10,000xg for 20 min. The S2 was ultracentrifuged at 100,000xg g
to obtain the pellet (P3 containing the vesicle fraction). Protein content was determined using
the Bradford protein assay. Equal amount of protein extracts were loaded into the SDS-PAGE.
Western blot analysis
Western blot analysis was performed as previously described [20]. Briefly, protein content was
determined using the Bradford protein assay. Equal amounts of protein extracts were resolved
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by standard sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Samples were electro-
blotted onto Protan nitrocellulose (GE Healthcare Life Sciences). Membranes were incubated
with 3% low-fat milk in 1X PBS-Tween 0.05% solution with the indicated antibody: anti-
LRRK2 (1:5000 MJFF2 c41-2 Epitomics), anti-Flag (F3165 1:2500 Sigma-Aldrich), anti-DRD1
(D2944 1:2000 Sigma-Aldrich), anti-beta-actin (A5441 1:5000 Sigma-Aldrich), Phospho-p44/
42 MAPK (Thr202/Tyr204) (9101 1:1000 Cell Signalling) for 16 h at 4˚C. Goat anti-mouse
immunoglobulin G (IgG) peroxidase-conjugated antibody (1:2500 Millipore Corporation) or
goat anti-rabbit IgG peroxidase-conjugated antibody (1:5000 Millipore Corporation) were
used to reveal immunocomplexes by enhanced chemiluminescence (Pierce Biotechnology,
Rockford, IL, USA).
Primary striatal cultures
Primary midbrain cells were prepared from postnatal C57black/J6 P0 mice brains. Briefly, tis-
sues from 8–9 pups were dissociated with 199 units of Papain and 0,1% DNase (Worthington
Biochemical Corporation) in 5ml of Earle’s Balanced Salt Solution (EBSS) for 30 minutes at
37˚C, followed by trituration. Enzymatic digestion was stopped with EBSS containing papain
inhibitor. Intact cells were separated from cell debris by centrifugation through a single step of
discontinuous density gradient in presence of 10mg/ml serum bovine albumin and 10mg/ml
ovomucoid in EBSS. Cellular pellet was then resuspended in Neurobasal media (Life Technol-
ogies) supplemented with 2% v/v of B27 (Invitrogen), 0.5 mM L-glutamine (Life Technolo-
gies), penicillin (100 units/ml) streptomycin (100 μg/ml) and 2.5 μg/ml fungizone (Life
Technologies). Cells were then plated at a density of 2 × 105 cells/well on poly-L- lysine-coated
wells (0.1 mg/ml, Sigma Aldrich) in a 24-well plate and cultured at 37 ˚C in 5% CO2. At DIV7
neurons were treated with 10μM dopamine for 15 or 60 minutes, fixed in 4% paraformalde-
hyde and then processed for immunofluorescence. Fluorescent images of D1 positive neurons
were acquired using a Zeiss LSM 700 confocal microscope equipped with a 63× oil objective.
8–10 images/replicate/condition were taken from a single z-plane at a thickness of 2,2 μm and
exposure settings for the 488 fluorochrome were kept constant across images and experiments.
Neuronal images were analyzed by using the Analyze particle macro of ImageJ and the area of
D1 fluorescent puncta was measured. Two independent primary culture preparations (from 8
pups each) were used per genotype and per condition. Images of twenty DRD1 positive neu-
rons were taken for each experimental point per genotype. In all neuronal pictures, D1 puncta
distribution was scored as diffuse, neuritic or somato-neuritic and reported as percentage of
total D1 positive neurons.
Immunofluorescence
For cells: 1×105 SH-SY5Y-DRD1 or SH-SY5Y-DRD2 cells, grown on a cover-glass, were
washed twice with PBS 1X and then fixed with 4% paraformaldehyde/PBS for 10 min. Cells
were permeabilized with 0.1% Triton X-100 diluted in PBS. For tissue: after apomorphine
hydrochloride (3mg/Kg) treatment the mice were sacrificed. The brains were embedded in
OCT freezing medium and 10 μm-thick sections were prepared by cryostat. All sections were
fixed with 4% paraformaldehyde/PBS for 15 min and washed with 0.05% Tween-20 diluted in
PBS. Non-specific binding was blocked with 5% bovine serum albumin, 0.05% Tween-20
diluted in PBS for 1 h at room temperature. Cells or tissue were incubated with primary anti-
bodies: anti-LRRK2 (1:500 Mjff2 c41-2 epitomics), anti-Flag (1:2500 Sigma-Aldrich), anti-
alpha-synuclein (1:500, Millipore), anti-DRD1 (1:1000, Sigma-Aldrich), anti-H4 histone
(1:5000, Sigma-Aldrich), anti-TGN46 (MBS223409, 1:1000 Mybiosource), mouse anti-beta III
tubulin (clone 2G10, 1:500 Sigma) diluted in blocking solution, overnight at 4˚C. Cells were
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then washed with PBS, 0.05% Tween-20 diluted in PBS and incubated with secondary antibod-
ies: Goat anti-Mouse IgG Secondary Antibody Alexa Fluor1 488 (Life Technologies) and Goat
anti-Mouse IgG Secondary Antibody Alexa Fluor1 647 (Life Technologies) diluted 1:1000 in
blocking solution for 1 hour at room temperature. Golgi staining was performed with Wheat
Germ Agglutinin Alexa Fluor1 633 Conjugate (Life Technologies). Before analysis, cells were
mounted using Mowiol mounting medium and fluorescence was revealed with a Leica TCS
SP5 confocal microscope with LAS lite 170 image software. For the statistical analysis, four
independent animals and at least 10 different confocal pictures (high magnification) for each
animal were analysed and scored for any experimental point. For DRD1 localization on tissue
sections, "dotted cells" indicate cells with marked green spots around the nucleus.
Intracellular cAMP determination
SH-SY5Y-DRD1 cells were incubated in sterile 96-well plate with a seeding density of 1x104
cells per well. Cells were cultured in DMEM-F12 10% FBS during 24 hours and transduced by
adenovirus encoding LRRK2s for 48 hours. Medium was replaced by serum-free medium con-
taining 10μM Dopamine hydrochloride, 500μM IBMX and 100μM Ro 20–1724 and incubated
for different times. Intracellular cAMP level measurement was performed using cAMP-Glo
assay kit according to manufacturer’s instruction (Promega Corporation). Luminescence was
measured using the Victor™ X5 Multilabel Plate Reader (PerkinElmer)
Quantitative real time RT-PCR
Quantitative real-time PCR was performed on the Qiagen Rotor-Gene1 Q, using the BioRad
iTaq™ Universal SYBR1 Green Supermix kit. Triplicate PCR reactions were performed follow-
ing the manufacturer’s recommended amplification conditions. For all the analyses, the ampli-
fication of GADPH transcripts has been used as reference for normalization. The final PCR
products were quantified using ΔΔCt method. The following primer pairs were used:
LRRK2 (fw GATTTCACCATTCAGAAACTC and rv CATGACATTTTTAAGGCTTCC)
GADPH (fw TCACCATCTTCCAGGAGCGAG and rv ACAGCCTTGGCAGCACCAGT)
Statistical analysis
The results are presented as means ± S.D. or S.E.M. of at least n3 independent experiments.
Two independent experiment were performed for in vivo analysis (primary cultures and trans-
genic animals). Statistical evaluation was conducted by one-way ANOVA (for comparisons
between genotypes at a single time point) or two-way ANOVA (for comparisons between
genotypes over time) and Bonferroni post test. Values significantly different from the relative
control are indicated with an asterisk. p<0,05; p<0,01; p<0,001.
Supporting information
S1 Fig. Analysis of DRD1 internalization upon dopamine treatment in SH-SY5Y-DRD1
cells untransduced or transduced by WT or mutant G2019S LRRK2. (A and B) DRD1 local-
ization upon 5 (A) or 60 minutes (B) of dopamine treatment of SH-SY5Y-DRD1 cells trans-
duced by the different recombinant adenovirus for 48h. After agonist treatment, the cells were
fixed and incubated with the appropriate primary antibodies (anti-FLAG for DRD1 and anti-
LRRK2 (MJFF2) for LRRK2) and with Alexa647-conjugated secondary antibody (red) or Alex-
a488-conjugated secondary antibody (green) for DRD1 or LRRK2 respectively. Scale
bars = 10μm.
(TIF)
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S2 Fig. (A and B) DRD1 localization at basal level (A) or upon 15 minutes (B) of dopamine
treatment of SH-SY5Y-DRD1 as in Fig 1 with or without 4 hours of CZC25126 pre-treatment.
After agonist treatment, the cells were fixed and incubated by the different primary antibodies
(anti-FLAG for DRD1 and anti-LRRK2 (MJFF2) for LRRK2) and with Alexa647-conjugated
secondary antibody (red) or Alexa488-conjugated secondary antibody (green) for DRD1 or
LRRK2 respectively. Scale bars = 10μm. (C) Quantification of the average (mean ± SEM) of D1
puncta area from each image from two independent experiments showed in Fig 7B, 7D and
7E. p<0,01; p<0,001. Two-way ANOVA and Bonferroni post test were used.
(TIF)
S3 Fig. (A and B) Analysis by western blot of DRD1 protein level on total, membrane or vesi-
cle protein fraction purified from striatum of WT or G2019S knock-in mice treated (B) or not
(A) by apomorphine. (C) Analysis of DRD2 mRNA by real time PCR in the presence of WT or
G2019S LRRK2 mutant in the same experimental conditions of Fig 4.
(TIF)
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